Download Files:
Products Details
Product Description
– Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc[1].
Web ID
– HY-13241A
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C24H29FN6
Citations
– Cell Biol Int. 2019 Jul 19.|Commun Biol. 2022 Dec 20;5(1):1391.|Eur J Immunol. 2020 Sep;50(9):1350-1361.|Glia. 2020 Jan;68(1):27-43. |bioRxiv. 2023 Feb 8.|Cell Death Dis. 2021 Oct 23;12(11):994.|Cell Rep. 2023 Mar 20;42(3):112275.|EBioMedicine. 2015 Nov 19;2(12):1944-56. |Harvard Medical School LINCS LIBRARY|Mol Med Rep 2019 Jul;20(1):735-744.|Nat Commun. 2021 Dec 3;12(1):6941.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
References
– [1]Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74.
CAS Number
– 862505-00-8
Molecular Weight
– 420.53
SMILES
– NC1=NC2=CC=C(C3=C(C4=CC=C(F)C=C4)N=C(C(C)(C)C)N3)N=C2N1CC(C)(C)C
Clinical Information
– Phase 2
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Autophagy;p38 MAPK
Isoform
– p38α;p38β
Pathway
– Autophagy;MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
